Janssen Presents P-Ib/II (CHRYSALIS-2) Study Results of Rybrevant (amivantamab-vmjw) for Non-Small Cell Lung Cancer and EGFR Mutations at IASLC 2022
- The P-Ib/II (CHRYSALIS-2) study evaluate Rybrevant + lazertinib & Pt-based CT (carboplatin & pemetrexed) in patients with r/r NSCLC & EGFR mutations
- The results showed 50% ORR in 15 out of 20 patients remaining on treatment after a median follow-up of 7.1mos. The safety profile was consistent with the prior reported safety profile of each agent with new safety signals or additional toxicity
- The updated results from the treatment-naïve cohort of the P-I (CHRYSALIS) study showed a confirmed response (ORR of 100%), 70% were progression-free & remained on therapy, m-DoR & m-PFS were not reached after a median follow-up of 22.3mos., 2 patients have remained on treatment after disease progressed
Ref: PRNewswire | Image: Janssen
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.